AUM Biosciences welcomes Terig Hughes as its Chief Financial Officer
AUM Biosciences (AUM), a Singapore-based company officially welcomes Terig Hughes as its Chief Financial Officer. AUM is focused on the development of innovative and affordable oncology medicines for cancers with high unmet medical needs in Asia.
About Terig Hughes
Terig Hughes brings with him over 25 years of international experience in healthcare, scientific and medical publishing, information and analytics, including print to digital migration. Terig’s M&A experience spans Europe, USA and Asia, with portfolios of up to $400m in annual turnover. He has also been recognized for closing significant deals such as a $2m Joint Venture formation with the prestigious Peking University in Beijing to provide online medical education, as well as, the integration of a $4.5B acquisition in USA.
“Every day, patients with cancer experience life changing events. A great proportion of them will struggle to get access to appropriate and affordable treatment. At AUM Biosciences, our aspiration is to improve this situation by focusing on developing affordable new treatments for underserved populations where the burden of cancer is growing fastest,” said Terig Hughes, Chief Financial Officer, AUM Biosciences.
As the Managing Director, Health Solutions, India & South East Asia for Elsevier, Terig was responsible for growing a revenue publishing and information business valued at over $50 million. Focusing on medical education and clinical decision support, and driving transformation from print products to digital solutions, he grew penetration of digital reference products in hospitals from 3% to 12%.
“In the highly capital intensive drug development industry, we are delighted to have Terig on board our team. His financial know how will certainly improve AUM’s financial credibility in the industry,” said Vishal Doshi, Founder and CEO, AUM Biosciences.
With extensive financial management experience in growing businesses, Terig has also led change including finance transformation and business reorganizations. He is skilled at leading and managing cross-functional teams that are both culturally diverse and geographically dispersed.
“Terig is a highly talented financial manager with global and Asia-specific expertise in the healthcare sector. He has clearly established himself as a leader in this area and is a consummate change manager. We are very fortunate to have him as CFO at AUM,” said Harish Dave, Co-Founder, and Chief Medical Officer, AUM Biosciences.
Terig has held previous senior leadership roles in Asia with Elsevier, as Finance Director for the Health Sciences Division, and Managing Director for India and South East Asia. He led the restructuring of the organization’s Southeast Asia business to deliver $2m of operational expenditure savings, establishing a sustainable growth trajectory with healthy margins for the business.
He holds a Degree in Accountancy and Law from De Montfort University in the UK and graduated from the management development programme at University of Oxford.
AUM Biosciences is an oncology-focused biotechnology company that aims to accelerate the development of innovative, affordable cancer medicines for patients in Asia and around the world. AUM Biosciences focuses on early-stage development of innovative medicines for the treatment of Asian-prevalent cancers.
AUM Biosciences will have a specific focus on indications such as hepatocellular carcinoma, head and neck cancer, gastric cancer, cholangiocarcinoma, triple negative breast cancer, prostate and colorectal cancer. With a huge opportunity to identify targets for unmet medical needs, AUM Biosciences will partner and collaborate with leading research institutes, clinicians and pharmaceutical companies bringing new, affordable and effective therapies to patients in need.